Medtronic plc, a global leader in healthcare technology, has announced a strategic partnership with DASI Simulations, a pioneer in AI-powered predictive modeling and digital-twin technology. The collaboration aims to expand access to DASI’s technology in the United States, optimizing outcomes for patients undergoing transcatheter aortic valve replacement (TAVR).
This initiative marks an important milestone in both companies’ missions to deliver innovative, patient-specific cardiac care. By integrating DASI Simulations’ AI-based predictive modeling and digital twin technology into the TAVR workflow, clinicians will gain independent, device-agnostic insights to guide precise, individualized treatment decisions for patients with aortic stenosis.
"Effective pre-case planning is essential to achieving optimal outcomes in TAVR," said Matthew Summers, MD, interventional cardiologist at Sentara Heart Hospital. "Integrating DASI's predictive modeling into our workflow has allowed us to better visualize anatomy, anticipate risks, and tailor valve decisions to each patient. It's helped us focus on individual factors like annular rupture, coronary occlusion, and paravalvular leak, while also planning for future reinterventions."
According to Teri Sirset, MS, founder, president, and chief executive officer of DASI Simulations, "Partnering with Medtronic accelerates our mission to bring scalable, AI-powered planning tools to structural heart programs nationwide. Together, we're demonstrating how predictive modeling can drive operational efficiency, support clinical decision-making, and elevate the standard of care."
DASI’s FDA-cleared platform uses real patient CT anatomies and retrospective outcome data to simulate multiple transcatheter heart valve (THV) deployment scenarios. These data-driven, device-agnostic reports are designed to help mitigate human error, predict complications, and optimize long-term management for patients with structural heart disease.
"The future of TAVR lies in delivering patient-specific, data-driven care that spans the full patient journey, from therapy awareness and innovation to procedural excellence and options for future intervention," said Jorie Soskin, vice president and general manager of the Structural Heart business within Medtronic’s Cardiovascular portfolio.
Participating sites will receive comprehensive support from both Medtronic Structural Heart and DASI Simulations teams. The program aims to demonstrate the clinical and operational benefits of simulation-based planning, reinforcing the value of device-agnostic, patient-specific TAVR care.
"We are entering a new era in structural heart care, guided by predictive AI models that help the physician determine the best treatment personalized for each patient, rather than relying on statistical norms. This shift to precision medicine will transform how we treat structural heart diseases," said Lakshmi Dasi, PhD, founder and chief technology officer at DASI Simulations. "DASI is the pioneer for AI-based predictive modeling for TAVR, and our platform is designed to support unbiased and device agnostic decision-making with the patient at the center that will ultimately support more confident, personalized interventions."
Also Read
